glp-1 cardiovascular outcomes trial results august 2025 Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials - Yin - ISPOR 2025: Exploring reasons for

At a glance Status : Confirmed GLP-1 receptor agonist use (specific drug not publicly disclosed) Medical context : Pre-existing autoimmune thyroid condition requiring medication Timeline : Public confirmation in 2024 interviews Discontinuation status : Not publicly confirmed whether she has stopped or continues treatment Clinical focus of this page : What peer-reviewed evidence says about GLP-1 discontinuation, regain risk, and maintenance in patients with thyroid comorbidities The Discontinuation Problem: What the Trials Show The single most replicated finding in GLP-1 obesity research is that stopping the medication leads to weight regain

The defining structural feature is a side-chaintoside-chain lactam bridge formed between the -carboxyl of Asp(2) and the -amine of Lys(7), producing a homodetic isopeptide macrocycle

The researchers plan to repeat the study using other drugs that alter excitation and inhibition whose mechanisms are better understood, says McAlonan

It appears to affect nitric oxide, a molecule your body uses to regulate blood flow